An observational study in Neurocognitive Disorders, Mild, Cognitive Impairment, Mild and Depression Mild, sponsored by KompanionCare SAS. Recruiting at 5 sites in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by KompanionCare SAS · Observational
Among 43 studies in Neurocognitive Disorders with a site in France — 20 open to participants now, 23 under way, none of them phase 3. Neurocognitive Disorders · France.
Among the 43 studies in Neurocognitive Disorders with a site in France, this one is the 15th largest by planned enrollment of the 19 observational ones, is one of 5 that started in 2025, is one of 19 observational ones, reaches primary completion later than 8 of the 22 other live ones, and was the 38th registered.
274 studies on the registry are indexed under Neurocognitive Disorders; 90 are open to participants now.
This study's planned enrollment of 80 is below the median of 150 across 96 observational studies indexed under Neurocognitive Disorders.
Browse Neurocognitive Disorders studies →20 of the 43 studies in Neurocognitive Disorders with a site in France are open now, in 12 countries. Each count lists the studies.
Of the 59 Neurocognitive Disorders studies recruiting now, 36 (61%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →43 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2025.
Median enrollment 58 across the 24 interventional studies, 135 across the 19 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
11 of 43 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with KompanionCare SAS as lead sponsor.
KompanionCare SAS has 1 study filed under Neurocognitive Disorders — fewer than ten, so there is no comparison to draw.
8 of the studies in Neurocognitive Disorders with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07237009KompanionCare SASEffects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders | 2026-12 |
| NCT05586672Etablissement Public de Santé Barthélemy DurandHR-EEG Contribution in Prognostic Evaluation of Language Development in Children With ASD | 2027-01-31 |
| NCT07468305Centre Hospitalier Universitaire de NiceSENS'REM - SENSoriality and Multi-Sensory Emotional Reminiscences: a Pilot Study | 2027-02 |
| NCT05129150University Hospital, ToursCognitive Disorders and Brain Pulse | 2027-03 |
| NCT06801171Centre Hospitalier Universitaire de NiceA Mixed Intervention to Improve Resilience for Patient With Neurocognitive Disorders | 2027-05-01 |
Among the 43 studies in Neurocognitive Disorders with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.
The researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.
The study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.
Participants will:
Participants will be recruited during routine visits at five French university hospital geriatrics/memory clinics.
The source population comprises older adults followed in these services who live mainly at home or in hospital-based residential settings. The study focuses exclusively on patients with mild neurocognitive disorder or mild dementia, and includes individuals with mild depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single observational cohort exposed to a personalized digital reminiscence therapy, through daily 10-15 minute sessions.
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated scale of depressive symptom severity. Possible scores range from 0 to 60, with higher scores indicating more severe depression. Decrease of MADRS total score between two measurement points indicates improvement over time. Unit of Measure: points (from 0 to 60)
Time frame: Baseline, Day 25, Day 50.
Change in Lille Apathy Rating Scale (LARS) Total Score
The Lille Apathy Rating Scale (LARS) is a clinician-rated questionnaire assessing apathy with a total score from -36 to +36. Higher scores indicating greater apathy. Decrease of LARS total score between two measurement points indicates improvement over time. Unit of Measure: points (from -36 to +36).
Time frame: Baseline, Day 25, Day 50.
Change in The Short Form Survey (SF-36) Global Score.
The Short Form Survey (SF-36) measures health-related quality of life. Scores range from 0 to 100, with higher scores indicating better health status. Increase of SF-36 global score between two measurement points indicates improvement over time. Unit of Measure: Points on SF-36 scale from 0 to 100.
Time frame: Baseline, Day 25, Day 50.
Change in Pittsburgh Sleep Quality Index (PSQI) Global Score
The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire evaluating sleep quality with scores from 0 to 21, with higher scores indicating worse sleep quality. Decrease of PSQI global score between two measurement points indicates improvement over time. Unit of Measure: Points on PSQI scale from 0 to 21.
Time frame: Baseline, Day 25, Day 50.
Number of Sessions Completed
Counting the number of sessions completed by the patient between Baseline and Day 25. Higher numbers are indicating greater adherence to the application use. Unit of Measure: Number of Sessions Completed
Time frame: From Baseline to Day 25
Average Self-Reported Session Duration
Average self-reported session duration is the approximate average time spent per session with using the Lilia application between Baseline and Day 25 based on the patients' own observations. It is measured by a dedicated question: "On average, how much time did you spend with Lilia when you used it?" (response options: "Less than 5 minutes," "5-10 minutes," "More than 10 minutes"). Higher values refers to longer average sessions. Unit of Measure: average minutes per session
Time frame: From Baseline to Day 25.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.
Of 53 observational studies under Neurocognitive Disorders, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 78. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.